Mimosa Therapeutics

Mimosa is a public benefit corporation that aims to offer psilocybin (and complementary molecules) grown in microbrewer vast. The team behind the company includes psychedelic veterans like Amanda Fielding.

Mimosa Therapeutics

From the website: “MIMOSA is drastically changing the market by offering all-natural psilocybin, grown as mycelia (“roots” of mushrooms) in scalable “brewers.” Mimosa’s psilocybin brewers can range in size from ~ 2 gallon microbrewers to 50,000 gallon brew vats. The process can be 100% organic (OMRI – Organic Materials Review Institute) compliant, requiring no genetic modifications, no synthetic chemistry and no solvents of any kind. This creates consistent full-spectrum psilocybin, with options for pure psilocybin as well as for measured combinations with baeocystin and other complementary molecules, that is cleaner, less expensive, and superior in quality to traditionally offered entheogenic mushrooms or truffles.”

The company builds further on previous work by OLP Therapeutics.

Key Staff

• Amanda Feilding – Co-Founder & Director
• Jim Keim – Co-Founder & CEO
• Felix Blei – Chief Analytics Officer

Media

• A New Approach to Psilocybin Production That’s Cheaper and More Precise: Mimosa CEO Jim Keim (Psychedelic Invest, February 2021)